A tripyridylamide-based small molecule (ADH-6) was recently reported to abrogate mutant p53 aggregation and restore its tumor suppressor activity in cell culture and xenograft models (Palanikumar et al., 2021). The gene discussed is TP53; the disease is neoplasm.